AB0277 Leptin and adiponectin levels in rheumatoid arthritis patients. (12th June 2018)

• Record Type: Journal Article
• Authors: Nicolaou, N.; Joseph, J.; Bruce, I.N.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 1318
• Page End: 1318
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.1189
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Rheumatoid Arthritis (RA) is a chronic inflammatory autoimmune disorder characterised by systemic inflammation of joints, in particular the synovial membrane, cartilage and bone. Leptin (LEP) and adiponectin (ADIP) belong to a distinct group of biological molecules, adipokines which are secreted by white adipose tissue and have a central role in energy storage and metabolism. Objectives: To compare fasting serum LEP and ADIP in RA to healthy controls and to investigate whether fasting LEP and ADIP serum levels change following a change in RA treatment. Methods: Male and female subjects aged 18 years old or above with RA, fulfilling the 2010 ACR/EULAR classification criteria and having DAS28 score >4.2, were recruited and followed up for 90 days. LEP and ADIP levels were measured using ELISA. Fasting glucose, lipids and insulin levels were also measured as indicating factors for co-morbidities. The associations between RA patients at baseline and controls were assessed by uncorrelated/unrelated t-test analyses while associations between RA patients at baseline, day 30 and day 90 were assessed by one-way correlated/related analysis of variance. Results: We studied 30 RA patients with mean (SD) age of 56.33 (13.84) years, of whom 24 (80%) were female and 15 healthy individuals with mean (SD) age of 53.80 (13.97) years, of whom 12 (80%) were female. LEP and ADIP levels for control subjects were 28.36 (15.08) ng/mL (p=NS vs RA at baseline) and 14.76 (4.42) μg/mL (p<0.05 vs RA at baseline) (table 1). Over 90 days DAS28 and HAQ score improved significantly in RA patients. LEP levels for RA patients were 29.65 (18.17) ng/mL at baseline, 30.81 (17.65) ng/mL at day 30 and 25.90 (15.01) ng/mL at day 90 (p=NS) whilst ADIP levels for RA patients were 16.78 (8.73) μg/mL at baseline, 16.65 (8.70) μg/mL at day 30 and 15.44 (7.24) μg/mL at day 90 (p=NS) (table 2). Conclusions: ADIP was significantly higher in RA patients at baseline compared to control subjects and there was a trend towards normalisation of levels as inflammation improved. The role of ADIP in active RA remains unclear and further examination of the site of origin of ADIP as well as its role in pro- and anti-inflammatory pathways warrants further study. Disclosure of Interest: None declared